Effects of oral anticoagulation with various INR levels in deep vein thrombosis cases by Yetkin, Ufuk et al.
BioMed  Central
Page 1 of 4
(page number not for citation purposes)
Current Controlled Trials in 
Cardiovascular Medicine
Open Access Research
Effects of oral anticoagulation with various INR levels in deep vein 
thrombosis cases
Ufuk Yetkin*1, Özalp Karabay2 and Hakan Önol3
Address: 1İzmir Atatürk Education and Research Hospital, Department of Cardiovascular Surgery, TURKEY, 2İzmir 9 September Medical Faculty 
Hospital, Department of Cardiovascular Surgery, TURKEY and 3İzmir Alsancak State Hospital (Ancien Hôspital Françias – 1908), TURKEY
Email: Ufuk Yetkin* - ozalp.karabay@deu.edu.tr; Özalp Karabay - ozalp.karabay@deu.edu.tr; Hakan Önol - ozalp.karabay@deu.edu.tr
* Corresponding author    
Deep venous thrombosisWarfarinINRrisk of hemorrhage
Abstract
Aim: In order to avoid the complications associated with thromboembolic disease, patients with
this condition typically are placed on long-term anticoagulant therapy. This report compares
bleeding complications in this patient population by level of achieved INR.
Materials and Methods: During the 6-year period between January 1997 and January 2003, 386
patients with venous thromboembolism of the lower extremities were admitted to the
Cardiovascular Surgery Outpatient Clinic of Alsancak State Hospital. Of the 386 patients, 198
(51.2%) were women, and the average age was 52.3 years. All diagnoses of venous
thromboembolism were confirmed by means of Doppler ultrasonography. Further investigation
showed occult neoplasms in 22 (5.6%) of the cases. We excluded the patients with occult disease,
and the remaining 364 constituted our study population.
Results: Oral anticoagulation was standardized at 6 months' duration in all cases. We divided the
patients into two groups. Group I consisted of 192 patients (52.7%) with INR values between 1.9
and 2.5; Group II comprised 172 patients with INR values between 2.6 and 3.5. Complications in
each group were assessed and compared. The minor hemorrhage rate was 1.04% in Group I and
4.06% in Group II. The major hemorrhage rate was also 1.04% in Group I and was 6.3% in Group
II. We determined that the complication rates for both minor and major hemorrhage were
significant in patients with INR values above 2.5.
Conclusion:  Oral anticoagulation must be followed closely in patients with venous
thromboembolism. Higher INR levels are associated with significant increases in hemorrhage and
associated complications. INR values of 2.0 to 2.5 are sufficient for long-term anticoagulant therapy,
ensuring ideal anticoagulation levels and minimizing the complication rate.
Background
Deep vein thrombosis (DVT) is the presence in lower-
extremity veins of a thrombus that obstructs the branches
and blood flow. The natural course of DVT therapy is asso-
ciated with significant morbidity and mortality rates [1].
Standard therapy for acute DVT consists of heparin fol-
lowed by oral warfarin [2]. To monitor therapy with cou-
madin anticoagulants, prothrombin time (PT) was the
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standard until as recently as the past decade [3]. Because
the therapeutic range of PT depends on many factors,
comparing patient results and assessing the significance of
those results can be difficult. Therefore, the World Health
Organization (WHO) developed an international stand-
ardization system known as the international normalized
ratio (INR) [4].
We monitored anticoagulation therapy and compared
bleeding complications among outpatients with lower-
extremity DVTs who were taking oral anticoagulants
(OACs) and who exhibited two different ranges of INR
values.
Materials and Methods
Between January, 1997 and January, 2003, 386 patients
with a preliminary diagnosis of venous thromboembo-
lism were admitted to the Cardiovascular Surgery Outpa-
tient Clinic at Alsancak State Hospital. Of these patients,
198 (51.2%) were women and 188 (48.4%) were men.
The average age of all patients was 52.3 years (range, 23–
81 years). In all cases, the diagnosis of venous throm-
boembolism was confirmed by means of Doppler ultra-
sonography (USG). When admitted, no patients in the
study group were known to have malignant disease as the
etiologic factor of DVT. We excluded patients with super-
ficial thrombophlebitis, thrombosis, and recurrent DVT.
To investigate for tumors and establish the diagnoses, we
used chest radiographs and laboratory tests (erythrocyte
sedimentation rate, C-reactive protein, complete blood
count, urea, creatinine, serum glutamic oxaloacetic
transaminase [SGOT], serum glutamic pyruvic transami-
nase [SGPT], gamma glutamyl transferase [gamma GT],
alkaline phosphatase [ALP], bilirubin, electrophoresis,
total protein, alpha fetoprotein [α-FP], fibrinogen, cancer
antigen 19-9 [CA-19-9], and in men prostate-specific anti-
gen [PSA]). Abdominal ultrasonography was also used if
indicated. We identified previously unrecognized neo-
plasms in 22 (5.6%) patients (Table 1). We referred these
patients to oncology clinics and limited our study popula-
tion to the remaining 364 patients. Of this group, 42
(11.5%) were hospitalized for an average of 5.2 days and
received intravenous (IV) heparin plus oral anticoagu-
lants. We combined low-molecular-weight heparin
(LMWH) with oral anticoagulants for the other patients
and followed them in our outpatient clinic. For long-term
anticoagulation we used the same drug (coumadin) and
monitored results as INR values.
Results
We standardized oral anticoagulant therapy for a 6-month
period in all patients and followed them at our outpatient
clinic with bleeding profile tests. We classified the patients
according to INR values. The INR level was between 1.9
and 2.5 in Group I and between 2.6 and 3.5 in Group II.
Group I comprised 192 (52.7%) patients; Group II con-
sisted of 172 (47.3%) patients. During the 6-month con-
trol period, no mortality or major morbidity such as
pulmonary embolus occurred in either group, and we
found no recurrent DVT among the 343 (94.2%) patients
during that period. In Group I, two patients (1.04%) expe-
rienced minor hermorrhagic complications (subconjunc-
tival hemorrhage and epistaxis), and two patients
(1.04%) had major hemorrhagic complications (gastroin-
testinal [GI] bleeding and hemarthrosis). In Group II,
seven patients (4.06%) had minor hemorrhagic complica-
tions including skin necrosis in three, epistaxis in three,
and subconjunctival hemorrhage in three. Eleven patients
(6.3%) in Group II experienced major hemorrhagic com-
plications including GI bleeding in six, vaginal bleeding
in three, hemarthrosis in one, and gluteal hematoma in
one (Table 2). We noted no instances of noncompliance
and no major hematologic problems such as hemolysis
during follow-up. Among six patients with GI bleeding,
endoscopy demonstrated peptic ulcer disease in four
(66.6%) and acute erosive gastritis in two (33.3%). In
three patients with vaginal bleeding, two cases were due to
myoma uteri and one was a result of chronic cervicitis.
None of the hemorrhagic complications was secondary to
malignancy in either Group I or Group II. The patients in
Group II, whose INR values were between 2.6 and 3.5,
had significantly more minor and major bleeding compli-
cations than did patients in Group I.
Discussion
In 1977, the Committee on Thrombosis and Hemostasis
and the National Institute of Biological Standards and
Control (NIBSC) in London prepared a thromboplastin
material from human brain. This material was coded as
"67/40" and was accepted as an international reference
preparation by the WHO [5]. Because PT results are
dependent upon a number of factors, rates and activity
percentages with different thromboplastins may be incon-
sistent for an individual patient. The WHO introduced an
international standardization system [6], and in 1983 the
Table 1: Characteristics of patients admitted with lower 
extremity venous thromboembolism prediagnosis and found to 
have various occult malignancies
System with occult malignancy Cases
Ovarian Ca 6
Colon Ca 5
Bladder Ca 5
Lung Ca 3
Prostate Ca 2
Extensive genital Ca + peritonitis carcinomatosa 1
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Expert Committee on Biological Standardization of the
WHO accepted the international normalized ratio (INR)
for PT standardization (Table 3).
Since 1983, INR values have been calculated based on ran-
domized study results involving laboratory evaluation of
OAC therapy. Based on these study findings, the optimal
therapeutic range was narrowed. In 1989, a new guide was
prepared by the American College of Chest Physicians. We
are now using that guide [7].
Warfarin is the most frequently used OAC because of its
perfect bioavailability and consistent effect in both acute
and chronic disease [8]. Today, INR values are used at
many institutions to evaluate OAC therapy (2,4,5,7,9).
Anticoagulants are used in two different concentrations:
low doses for INR values between 2.0 and 2.5 and high
doses for INR values between 2.5 and 3.5. A low-dose reg-
imen is used in the treatment of venous thrombosis or
pulmonary embolus as well as prophylactically to prevent
venous thrombosis. High-dose regimens are recom-
mended for high-risk patients with mechanical prosthetic
cardiac valves. Low doses have been shown to be safer
than high doses and just as effective for following patients
who undergo DVT therapy [3,7,9,10].
In patients whose INR levels exceed 2.5, the incidence of
hemorrhagic complications increases significantly
[8,9,11]. An occult GI lesion accounted for 70% of the GI
bleeds, and in 10%, bleeding during anticoagulant ther-
apy was due to malignancy [4]. Even with ideal anticoag-
ulant doses, GI and genitourinary bleeding are seen as a
result of underlying disease [4,12]. In our study, GI bleed-
ing occurred in both groups, and vaginal bleeding
occurred as a complication in Group II (Table 2).
Hasenkam and associates proposed an INR between 2.0
and 2.7, even for patients with valve replacements, to
minimize the incidence of bleeding as a complication and
the risk of thromboembolus [13].
Many studies address the effectiveness of LMWH in treat-
ing DVT, and this form of heparin therapy should be seri-
ously considered. LMWH eliminates many problems
related to the use of nonfractionated IV heparin [1,8,14].
Its bioavailability is high, and the once-daily subcutane-
ous injection regimen is sufficient because of its longer
half-life. LMWH decreases major hemorrhagic complica-
tions and thrombocytopenia as well as the incidence of
osteoporosis associated with heparin administration. The
single LMWH injection without the necessity of monitor-
ing anticoagulation offers a very attractive treatment
method. DVT can be treated without hospitalization, and
patients can return to daily activities and to work much
more quickly [14,15]. We used LMWH for 88.5% of our
patients.
In conclusion, OAC therapy must be closely monitored
during both acute and chronic periods. To compare and
standardize results reported by different centers, values
should be reported as INR. Bleeding and related compli-
Table 2: Complications in both groups, classified due to INR levels.
Group I (INR: 1.9–2.5)
(192 Patients)
% Group II (INR: 2.6–3.5)
(172 Patients)
%
Mortality - -
Pulmonary thromboembolism - -
Recurrent DVT - -
Minor hemorrhage complications 2 1.04 7 4.06
Subconjunctival hemorrhage 1 0.52 1 0.58
Epistaxis 1 0.52 3 1.7
Skin necrosis - - 3 1.7
Major hemorrhagic complications 2 1.04 11 6.3
GI bleeding 1 0.52 6 3.4
Hemarthrosis 1 0.52 1 0.58
Vaginal bleeding - 3 1.7
Gluteal hematoma - 1 0.58
DVT: Deep vein thrombosis GI: Gastrointestinal
Table 3: INR formulation
• INR: prothrombin time rateISI
• Example = found in patient PT: 17.9 second
normal PT: 12.2 second
ISI: 2.3
• INR: (17.9 / 12.2)2.3 = 2.4
• INR: International normalized ratio; PT: Prothrombin time; ISI: 
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cations increase as INR levels are increased. We suggest
that, ideally, the anticoagulant dosage should be adjusted
to achieve an INR between 2 and 2.5 in patients with DVT.
This dose level minimizes complications and is sufficient
to control anticoagulant therapy.
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